Your Health, We Care
Vemurafenib is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.
Limitation of Use: Vemurafenib is not indicated for treatment of patients with wild-type BRAF melanoma.
Vemurafenib is indicated for the treatment of patients with Erdheim-Chester Disease (ECD) with BRAF V600 mutation.
from FDA，2020.12
